Enhancing Blood Cancer Research with a New Lymphoma Panel
Integrated DNA Technologies (IDT), a leader in genomics solutions, has just expanded its product offering by introducing the Archer™ VARIANT Plex™ Lymphoma panel. This groundbreaking addition is making strides in blood cancer research, equipping researchers with innovative tools to detect and analyze lymphomas more effectively.
Introducing the Archer VARIANT Plex Lymphoma Panel
The Archer VARIANT Plex Lymphoma panel is specifically designed to identify single nucleotide variants, insertions, deletions, and copy number variations across 49 key genes related to B-cell and T-cell lymphomas. What makes this panel stand out is its versatility; researchers can use it on its own or integrate it with other Archer panels, tailoring it to their unique research needs.
Streamlined Customization and Use
This state-of-the-art solution allows researchers to enhance their blood cancer investigations. By providing options to customize or pair the panel with existing products, IDT improves the research process, ensuring scientists can adapt to the specific requirements of their studies. This flexibility is crucial in genomics, where emerging data can quickly shift focus.
The Significance of Blood Cancer Awareness
As highlighted during Blood Cancer Awareness Month, this panel reflects IDT's commitment to meeting the research community's needs as they tackle blood cancers that impact over 1.2 million people globally each year. With this sophisticated panel, IDT reinforces its dedication to advancing research that fosters a better understanding of and treatment options for blood cancer patients.
The Technology Behind Archer NGS Solutions
Archer NGS technology is well-known for its exceptional flexibility while maintaining high performance. Researchers can easily choose pre-designed panels and extend their capabilities by adding targets that fit their specific research situations. Innovations such as Anchored Multiplex PCR (AMP™) chemistry enable compatibility with a range of sample types, including low-input or degraded specimens, like formalin-fixed paraffin-embedded tissue samples.
About Integrated DNA Technologies
For over 35 years, Integrated DNA Technologies, Inc. (IDT) has led the way in genomics. The company's advanced oligonucleotide manufacturing process distinguishes it in the industry, with superior synthesis, modification, purification, and quality control capabilities. Founded in 1987, IDT has evolved from a notable oligonucleotide manufacturer to a comprehensive provider of genomics solutions, supporting vital applications such as next-generation sequencing and CRISPR genome editing.
Strategic Acquisitions and Global Presence
IDT's recent acquisition of Archer™ NGS Research Assays in December 2022 exemplifies its commitment to enhancing its product offerings. This strategic decision aligns with IDT’s goal of streamlining the shift from lab-based research to real-world medical applications. With manufacturing facilities in key areas around the world, IDT takes pride in its ability to serve scientists and institutions globally, promoting collaborative advancements across various research domains.
Conclusion: A Commitment to Research Excellence
As part of the Danaher group of companies, IDT is uniquely positioned to deliver top-notch technology and expertise. This partnership enhances IDT’s capacity to provide comprehensive solutions that aim to translate scientific discoveries into meaningful health improvements. With a strong focus on genomics, cancer research, and innovative solutions, IDT remains dedicated to empowering researchers to achieve impactful advancements in healthcare.
Frequently Asked Questions
What is the Archer™ VARIANT Plex™ Lymphoma panel?
The Archer™ VARIANT Plex™ Lymphoma panel is a next-generation sequencing assay designed to detect genetic alterations relevant to blood cancer research.
How can researchers use this new lymphoma panel?
Researchers can use the panel independently or in combination with other panels, allowing for a customized approach tailored to their specific research requirements.
What advantages does IDT's technology offer?
IDT's Archer NGS technology offers unmatched flexibility and compatibility with various sample types, enhancing the overall research workflow.
What is IDT's mission?
IDT's mission is to accelerate the pace of genomics, enabling researchers to improve healthcare outcomes through enhanced scientific understanding.
How does IDT support the blood cancer research community?
IDT supports the blood cancer research community by providing advanced tools and technologies, as demonstrated by their latest Lymphoma panel release.
